Tal Patalon1,2, Sivan Gazit1,2, Virginia E Pitzer3,4, Ottavia Prunas3,4, Joshua L Warren3,5, Daniel M Weinberger3,4. 1. Kahn Sagol Maccabi Research and Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel. 2. Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel. 3. Public Health Modeling Unit, Yale School of Public Health, Yale University, New Haven, Connecticut. 4. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, Yale University, New Haven, Connecticut. 5. Department of Biostatistics, Yale School of Public Health, Yale University, New Haven, Connecticut.
Abstract
Importance: With the evidence of waning immunity of the mRNA vaccine BNT162b2 (Pfizer-BioNTech), a nationwide third-dose (booster) vaccination campaign was initiated in Israel during August 2021; other countries have begun to administer a booster shot as well. Objective: To evaluate the initial short-term additional benefit of a 3-dose vs a 2-dose regimen against infection of SARS-CoV-2. Design, Setting, and Participants: This preliminary retrospective case-control study used 2 complementary approaches: a test-negative design and a matched case-control design. Participants were included from the national centralized database of Maccabi Healthcare Services, an Israeli healthcare maintenance organization covering 2.5 million members. Data were collected between March 1, 2020, and October 4, 2021, and analyses focused on the period from August 1, 2021, to October 4, 2021, because the booster dose was widely administered from August 1 onward. Exposures: Either 2 doses or 3 doses of the BNT162b2 vaccine. Main Outcomes and Measures: The reduction in the odds of a positive SARS-CoV-2 polymerase chain reaction (PCR) test at different time intervals following receipt of the booster dose (0-6, 7-13, 14-20, 21-27, and 28-65 days) compared with receiving only 2 doses. Results: The study population included 306 710 members of Maccabi Healthcare Services who were 40 years and older (55% female) and received either 2 or 3 doses of the BNT162b2 vaccine and did not have a positive PCR test result for SARS-CoV-2 prior to the start of the follow-up period. During this period, there were 500 232 PCR tests performed, 227 380 among those who received 2 doses and 272 852 among those who received 3 doses, with 14 989 (6.6%) and 4941 (1.8%) positive test results in each group, respectively. Comparing those who received a booster and those who received 2 doses, there was an estimated odds ratio of 0.14 (95% CI, 0.13-0.15) 28 to 65 days following receipt of the booster (86% reduction in the odds of testing positive for SARS-CoV-2). Conclusion and Relevance: Previous studies have demonstrated that vaccine-derived protection against SARS-CoV-2 wanes over time. In this case-control analysis, we showed an association between receipt of the booster dose and a reduction in the odds of testing positive for SARS-CoV-2, potentially counteracting waning immunity in the short term. Further monitoring of data from this population is needed to determine the duration of immunity following the booster.
Importance: With the evidence of waning immunity of the mRNA vaccine BNT162b2 (Pfizer-BioNTech), a nationwide third-dose (booster) vaccination campaign was initiated in Israel during August 2021; other countries have begun to administer a booster shot as well. Objective: To evaluate the initial short-term additional benefit of a 3-dose vs a 2-dose regimen against infection of SARS-CoV-2. Design, Setting, and Participants: This preliminary retrospective case-control study used 2 complementary approaches: a test-negative design and a matched case-control design. Participants were included from the national centralized database of Maccabi Healthcare Services, an Israeli healthcare maintenance organization covering 2.5 million members. Data were collected between March 1, 2020, and October 4, 2021, and analyses focused on the period from August 1, 2021, to October 4, 2021, because the booster dose was widely administered from August 1 onward. Exposures: Either 2 doses or 3 doses of the BNT162b2 vaccine. Main Outcomes and Measures: The reduction in the odds of a positive SARS-CoV-2 polymerase chain reaction (PCR) test at different time intervals following receipt of the booster dose (0-6, 7-13, 14-20, 21-27, and 28-65 days) compared with receiving only 2 doses. Results: The study population included 306 710 members of Maccabi Healthcare Services who were 40 years and older (55% female) and received either 2 or 3 doses of the BNT162b2 vaccine and did not have a positive PCR test result for SARS-CoV-2 prior to the start of the follow-up period. During this period, there were 500 232 PCR tests performed, 227 380 among those who received 2 doses and 272 852 among those who received 3 doses, with 14 989 (6.6%) and 4941 (1.8%) positive test results in each group, respectively. Comparing those who received a booster and those who received 2 doses, there was an estimated odds ratio of 0.14 (95% CI, 0.13-0.15) 28 to 65 days following receipt of the booster (86% reduction in the odds of testing positive for SARS-CoV-2). Conclusion and Relevance: Previous studies have demonstrated that vaccine-derived protection against SARS-CoV-2 wanes over time. In this case-control analysis, we showed an association between receipt of the booster dose and a reduction in the odds of testing positive for SARS-CoV-2, potentially counteracting waning immunity in the short term. Further monitoring of data from this population is needed to determine the duration of immunity following the booster.
Authors: Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks Journal: N Engl J Med Date: 2020-12-30 Impact factor: 91.245
Authors: Marcus D Ruopp; Judith Strymish; Jonathan Dryjowicz-Burek; Katie Creedon; Kalpana Gupta Journal: J Am Med Dir Assoc Date: 2021-01-23 Impact factor: 4.669
Authors: Rosita Zakeri; Rebecca Bendayan; Mark Ashworth; Daniel M Bean; Hiten Dodhia; Stevo Durbaba; Kevin O'Gallagher; Claire Palmer; Vasa Curcin; Elizabeth Aitken; William Bernal; Richard D Barker; Sam Norton; Martin Gulliford; James T H Teo; James Galloway; Richard J B Dobson; Ajay M Shah Journal: EClinicalMedicine Date: 2020-10-09
Authors: Jeffrey Seow; Carl Graham; Blair Merrick; Sam Acors; Suzanne Pickering; Kathryn J A Steel; Oliver Hemmings; Aoife O'Byrne; Neophytos Kouphou; Rui Pedro Galao; Gilberto Betancor; Harry D Wilson; Adrian W Signell; Helena Winstone; Claire Kerridge; Isabella Huettner; Jose M Jimenez-Guardeño; Maria Jose Lista; Nigel Temperton; Luke B Snell; Karen Bisnauthsing; Amelia Moore; Adrian Green; Lauren Martinez; Brielle Stokes; Johanna Honey; Alba Izquierdo-Barras; Gill Arbane; Amita Patel; Mark Kia Ik Tan; Lorcan O'Connell; Geraldine O'Hara; Eithne MacMahon; Sam Douthwaite; Gaia Nebbia; Rahul Batra; Rocio Martinez-Nunez; Manu Shankar-Hari; Jonathan D Edgeworth; Stuart J D Neil; Michael H Malim; Katie J Doores Journal: Nat Microbiol Date: 2020-10-26 Impact factor: 17.745
Authors: Madhumita Shrotri; Annalan M D Navaratnam; Vincent Nguyen; Thomas Byrne; Cyril Geismar; Ellen Fragaszy; Sarah Beale; Wing Lam Erica Fong; Parth Patel; Jana Kovar; Andrew C Hayward; Robert W Aldridge Journal: Lancet Date: 2021-07-17 Impact factor: 79.321
Authors: Fabrizio Bert; Giacomo Scaioli; Lorenzo Vola; Davide Accortanzo; Giuseppina Lo Moro; Roberta Siliquini Journal: Int J Environ Res Public Health Date: 2022-06-13 Impact factor: 4.614
Authors: A Sarah Walker; David W Eyre; Koen B Pouwels; Jia Wei; Philippa C Matthews; Nicole Stoesser; Ian Diamond; Ruth Studley; Emma Rourke; Duncan Cook; John I Bell; John N Newton; Jeremy Farrar; Alison Howarth; Brian D Marsden; Sarah Hoosdally; E Yvonne Jones; David I Stuart; Derrick W Crook; Tim E A Peto Journal: Nat Commun Date: 2022-06-29 Impact factor: 17.694
Authors: David H Canaday; Oladayo A Oyebanji; Elizabeth White; Debbie Keresztesy; Michael Payne; Dennis Wilk; Lenore Carias; Htin Aung; Kerri St Denis; Maegan L Sheehan; Sarah D Berry; Cheryl M Cameron; Mark J Cameron; Brigid M Wilson; Alejandro B Balazs; Christopher L King; Stefan Gravenstein Journal: medRxiv Date: 2021-12-07